John Gregg, MBA

President & CEO

Start-up and pharmaceutical industry veteran, John M.H. Gregg, has extensive experience in forming and successfully exiting microbiome companies for investors. His expertise is in worldwide clinical development and commercialization of microbiological products, new anti-infectives, and oncology drugs, most recently with an FDA approval in September 2017 of Solosec (secnidazole). 

John established his reputation in senior marketing and new product planning roles at leading large drug companies including Pfizer, Novartis, Johnson & Johnson, and Bristol-Myers Squibb. John successfully launched Symbiomix Therapeutics, LLC, and LifeQual Pharmaceuticals, Inc., where he was the founding CEO.  John was also Executive Director of Commercial Operations for AkaRx, an oncology spinout of Astellas Pharma.

John holds a B.A. degree in biology (microbiology focus) from the University of Chicago and an M.B.A. in Marketing and International Business from the Leonard Stern School of Business at New York University. 

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

CEO John Gregg has over 35 years in the pharmaceutical industry and his past start-ups have successfully brought new anti-infective drugs to market.  John is uniquely qualified as he was previously responsible for new product planning for Pfizer for its picorna virus/rhino virus/coronavirus R&D program.

© 2020 BalinBac Therapeutics